(Stroke. 1995;26:254-258.)
© 1995 American Heart Association, Inc.
Articles |
Safety, Tolerability, and Pharmacokinetics of the N-Methyl-D-Aspartate Antagonist Dextrorphan in Patients With Acute Stroke
From the Stanford Stroke Center, Stanford University Medical Center, Stanford, Calif (G.W.A.); the Mercy General Hospital, Sacramento, Calif (R.P.A.); the University of Miami Medical Center, Miami, Fla (R.E.K.); and the Montefiore Medical Center, New York, NY (D.M.R.).
Background and Purpose Dextrorphan hydrochloride is a noncompetitive N-methyl-D-aspartate antagonist that is neuroprotective in experimental models of focal brain ischemia. The purpose of this study was to determine the maximum loading dose and maintenance infusion of dextrorphan hydrochloride that are well tolerated in patients with an acute stroke.
Methods An intravenous infusion of dextrorphan or placebo was begun within 48 hours of onset of a mild-to-moderate hemispheric stroke. Initially, patients were treated with either placebo (n=15) or dextrorphan (n=22) using a 1-hour loading dose (60 to 150 mg) followed by a 23-hour ascending-dose maintenance infusion (maximum total dose, 3310 mg). Subsequently, 29 patients were treated with dextrorphan in an open trial using a 1-hour loading dose (145 to 260 mg) followed by an 11-hour constant rate (30 to 70 mg/h) infusion.
Results Transient and reversible adverse effects, including nystagmus, nausea, vomiting, somnolence, hallucinations, and agitation, commonly occurred in dextrorphan-treated patients. Loading-dose escalation was stopped because of rapid-onset, reversible, symptomatic hypotension in 7 of 21 patients treated with doses of 200 to 260 mg/h. At the highest rates of maintenance infusion (>90 mg/h), 3 patients developed deep stupor or apnea. The maximum tolerated loading dose was 180 mg/h, and the maximum tolerated maintenance infusion was 70 mg/h. Maximum plasma levels of 750 to 1000 ng/mL were obtained in 9 patients. There was no difference in neurological outcome at 48 hours between the dextrorphan-treated and placebo-treated patients.
Conclusions The highest doses of dextrorphan administered were associated with serious adverse experiences in some patients. Lower doses (loading doses of 145 to 180 mg, maintenance infusions of 50 to 70 mg/h) were better tolerated and rapidly produced potentially neuroprotective plasma concentrations of dextrorphan. These doses were associated with well-defined pharmacological effects compatible with N-methyl-D-aspartate receptor antagonism.
Key Words: dextrorphan • N-methyl-D-aspartate antagonist • neuroprotection • stroke, acute
This article has been cited by other articles:
 |
|
 |
|
  H. P. Adams Jr, G. del Zoppo, M. J. Alberts, D. L. Bhatt, L. Brass, A. Furlan, R. L. Grubb, R. T. Higashida, E. C. Jauch, C. Kidwell, et al. Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation, May 22, 2007; 115(20): e478 - e534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. P. Adams Jr, G. del Zoppo, M. J. Alberts, D. L. Bhatt, L. Brass, A. Furlan, R. L. Grubb, R. T. Higashida, E. C. Jauch, C. Kidwell, et al. Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/ American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists Stroke, May 1, 2007; 38(5): 1655 - 1711. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Scallan Cerebral injury during paediatric heart surgery: perfusion issues Perfusion, July 1, 2004; 19(4): 221 - 228. [Abstract] [PDF]
|
|
|
|
|
|
H. P. Adams Jr, R. J. Adams, T. Brott, G. J. del Zoppo, A. Furlan, L. B. Goldstein, R. L. Grubb, R. Higashida, C. Kidwell, T. G. Kwiatkowski, et al. Guidelines for the Early Management of Patients With Ischemic Stroke: A Scientific Statement From the Stroke Council of the American Stroke Association Stroke, April 1, 2003; 34(4): 1056 - 1083. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Terada, T. Kazui, M. Takinami, K. Yamashita, N. Washiyama, and B. A. H. Muhammad Reduction of ischemic spinal cord injury by dextrorphan: Comparison of several methods of administration J. Thorac. Cardiovasc. Surg., November 1, 2001; 122(5): 979 - 985. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. K. Rokkas and N. T. Kouchoukos Update 2001: dextrorphan inhibits the release of excitatory amino acids during spinal cord ischemia Ann. Thorac. Surg., April 1, 2001; 71(4): 1397 - 1398. [Full Text] [PDF]
|
|
|
|
|
|
K. Uchino, D. Billheimer, and S. C. Cramer Entry Criteria and Baseline Characteristics Predict Outcome in Acute Stroke Trials Stroke, April 1, 2001; 32(4): 909 - 916. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Fisher and W. Schaebitz An Overview of Acute Stroke Therapy: Past, Present, and Future Arch Intern Med, November 27, 2000; 160(21): 3196 - 3206. [Full Text] [PDF]
|
|
|
|
|
|
J. J. Gangemi, J. A. Kern, S. D. Ross, K. S. Shockey, I. L. Kron, and C. G. Tribble Retrograde perfusion with a sodium channel antagonist provides ischemic spinal cord protection Ann. Thorac. Surg., June 1, 2000; 69(6): 1744 - 1748. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Weinbroum, V. Rudick, G. Paret, and R. Ben-Abraham The role of dextromethorphan in pain control Can J Anesth, June 1, 2000; 47(6): 585 - 596. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. M. Clark, E. C. Raps, D. C. Tong, and R. E. Kelly Cervene (Nalmefene) in Acute Ischemic Stroke : Final Results of a Phase III Efficacy Study Stroke, June 1, 2000; 31(6): 1234 - 1239. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Davis, K. R. Lees, G. W. Albers, H. C. Diener, S. Markabi, G. Karlsson, and J. Norris Selfotel in Acute Ischemic Stroke : Possible Neurotoxic Effects of an NMDA Antagonist Stroke, February 1, 2000; 31(2): 347 - 354. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Phase II Studies of the Glycine Antagonist GV150526 in Acute Stroke : The North American Experience Stroke, February 1, 2000; 31(2): 358 - 365. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G DEVUYST and J BOGOUSSLAVSKY Recent progress in drug treatment for acute stroke J. Neurol. Neurosurg. Psychiatry, October 1, 1999; 67(4): 420 - 425. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Andiné, N. Widermark, R. Axelsson, G. Nyberg, U. Olofsson, E. Mårtensson, and M. Sandberg Characterization of MK-801-Induced Behavior as a Putative Rat Model of Psychosis J. Pharmacol. Exp. Ther., September 1, 1999; 290(3): 1393 - 1408. [Abstract] [Full Text]
|
|
|
|
|
|
G. W. Albers, W. M. Clark, R. P. Atkinson, K. Madden, J. L. Data, and M. J. Whitehouse Dose Escalation Study of the NMDA Glycine-Site Antagonist Licostinel in Acute Ischemic Stroke Stroke, March 1, 1999; 30(3): 508 - 513. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Slyter Ethical Challenges in Stroke Research Stroke, August 1, 1998; 29(8): 1725 - 1729. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. H. Schlenker Dextromethorphan affects ventilation differently in male and female rats J Appl Physiol, November 1, 1996; 81(5): 1911 - 1916. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Dorman and P. A.G. Sandercock Considerations in the Design of Clinical Trials of Neuroprotective Therapy in Acute Stroke Stroke, September 1, 1996; 27(9): 1507 - 1515. [Full Text]
|
|